Denosumab biosimilar (Gedeon Richter)

地舒单抗生物类似药 (Gedeon Richter)

Report date: 2025/09/30 09:37:23

Base Information

Drug NameDenosumab biosimilar (Gedeon Richter)
Drug Alias NameDenosumab-QBDEYaxwerJunodENOBYXTRENBO +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor ligand superfamily member 11 inhibitors
TargetsTumor necrosis factor ligand superfamily member 11
Therapy Area/IndicationsBone metastasesGlucocorticoid-induced osteoporosisBone Resorption +[9] 
Global Approved IndicationsGlucocorticoid-induced osteoporosisBone ResorptionOsteoporosis, Postmenopausal +[8] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2025/06/23
Country/TerritoryCzechiaBulgariaUnited States +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGedeon Richter Plc
China Registration ClassN/A

Develop Information

Active CompaniesHikma Pharmaceuticals Usa IncHikma Pharmaceuticals PlcGedeon Richter Plc
Inactive CompaniesN/A
Active IndicationsBone metastasesGlucocorticoid-induced osteoporosisBone Resorption +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A